IP Library › Patent Application 16400262
Patent Application
App. No. 16/400,262

HIGH CONCENTRATION FORMULATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/400,262
Abstract

The present disclosure provides high concentration formulations of cortexolone-17α-propionate suitable for treating alopecia.

Claims (18)

1 . A pharmaceutical formulation, comprising cortexolone-17α-propionate, wherein said formulation provides a mean steady-state C max of cortexolone-17α-propionate of about 2 ng/ml to about 6 ng/ml after topical administration.

2 . The pharmaceutical formulation of claim 1 , wherein said formulation is administered twice daily.

3 . The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation is a semi-solid formulation.

4 . The pharmaceutical formulation of claim 3 , wherein the semi-solid formulation is a cream, a gel, a foam, or an ointment.

5 . The pharmaceutical formulation of claim 4 , wherein the semi-solid formulation is a cream.

6 . The pharmaceutical formulation of claim 1 , wherein the pharmaceutical formulation is a liquid.

7 . A pharmaceutical formulation, comprising cortexolone-17α-propionate, wherein said formulation provides a mean steady-state C max of cortexolone-17α-propionate less than about 3 ng/ml after topical administration.

8 . The pharmaceutical formulation of claim 7 , wherein said formulation is administered twice daily.

9 . The pharmaceutical formulation of claim 7 , wherein the pharmaceutical formulation is a semi-solid formulation.

10 . The pharmaceutical formulation of claim 9 , wherein the semi-solid formulation is a cream, a gel, a foam, or an ointment.

11 . The pharmaceutical formulation of claim 10 , wherein the semi-solid formulation is a cream.

12 . The pharmaceutical formulation of claim 7 , wherein the pharmaceutical formulation is a liquid.

13 . A pharmaceutical formulation, comprising cortexolone-17α-propionate, wherein said formulation provides a mean steady-state C max of cortexolone-17α-propionate less than about 2 ng/ml after topical administration.

14 . The pharmaceutical formulation of claim 13 , wherein said formulation is administered twice daily.

15 . The pharmaceutical formulation of claim 13 , wherein the pharmaceutical formulation is a semi-solid formulation.

16 . The pharmaceutical formulation of claim 15 , wherein the semi-solid formulation is a cream, a gel, a foam, or an ointment.

17 . The pharmaceutical formulation of claim 16 , wherein the semi-solid formulation is a cream.

18 . The pharmaceutical formulation of claim 13 , wherein the pharmaceutical formulation is a liquid.